Please use this identifier to cite or link to this item:
|dc.title||Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics|
|dc.identifier.citation||Dan, Y.-Y., Wai, C.-T., Lee, Y.-M., Sutedja, D.S., Seet, B.-L., Lim, S.-G. (2005-07-28). Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World Journal of Gastroenterology 11 (28) : 4344-4350. ScholarBank@NUS Repository.|
|dc.description.abstract||Aim: We set to determine factors that determine clinical severity after the development of resistance. Methods: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (37%) were non-cirrhotics with normal pre-treatment ALT (Group IA), 12/35 (34%) were non-cirrhotics with elevated pre-treatment ALT (Group IB), and 10/35 (29%) were cirrhotics (Group II). Patients were followed for a median of 98 wk (range 26-220) after the emergence of genotypic resistance. Results: Group IA patients tended to retain normal ALT. Group IB patients showed initial improvement of ALT with lamivudine but 9/12 patients (75%) developed abnormal ALT subsequently. On follow-up however, this persisted in only 33%. Group II patients also showed improvement while on treatment, but they deteriorated with the emergence of resistance with 30% death from decompensated liver disease. Pretreatment ALT levels and CPT score (in the cirrhotic group) were predictive of clinical resistance and correlated with peak ALT levels and CPT score. Conclusion: The phenotype of lamivudine-resistant HBV correlated with the pretreatment phenotype. The clinical course was generally benign in non-cirrhotics. However, cirrhotics had a high risk of progression and death (30%) with the development of lamivudine resistance. © 2005 The WJG Press and Elsevier Inc. All rights reserved.|
|dc.subject||Hepatitis B treatment|
|dc.description.sourcetitle||World Journal of Gastroenterology|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
checked on Feb 2, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.